Related Experiment Videos
Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia
Abstract:
In a double-blind, placebo-controlled trial in thirty patients with mild to moderate vascular dementia (VD) according to DSM-III-R criteria, the effects of the adenosine uptake blocker propentofylline (HWA 285) on regional cerebral glucose metabolism (rCMRGl) was studied using positron emission tomography of 2-[18F]fluoro-2-deoxy-D-glucose (FDG). 25 subjects completed the 3-months study. Propentofylline significantly improved relative rCMRGl in the motor cortex, while relative rCMRGl in the placebo treated group worsened significantly. Neuropsychologically, visual information processing was improved in the propentofylline group and we observed a trend towards a slowing of the progression of cognitive deterioration in patients with VD. The results of the longitudinal analysis showed further that neuropsychological and metabolic changes are closely related. These findings justify a large-scale clinical trial to prove therapeutic efficacy.
Insights
Propentofylline improved brain glucose metabolism in vascular dementia patients. This adenosine uptake blocker showed potential in slowing cognitive decline, suggesting further clinical trials are warranted.
Area of Science:
- Neuroscience
- Pharmacology
- Medical Imaging
Background:
- Vascular dementia (VD) is a progressive neurological disorder.
- Current treatments for VD have limited efficacy.
- Understanding metabolic changes in VD is crucial for developing new therapies.
Purpose of the Study:
- To investigate the effects of propentofylline, an adenosine uptake blocker, on regional cerebral glucose metabolism (rCMRGl) in patients with VD.
- To assess the impact of propentofylline on cognitive function and disease progression.
Main Methods:
- A 3-month, double-blind, placebo-controlled trial involving 30 patients with mild to moderate VD.
- Positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) was used to measure rCMRGl.
- Neuropsychological assessments were conducted to evaluate cognitive performance.
Main Results:
- Propentofylline significantly improved relative rCMRGl in the motor cortex compared to placebo.
- Visual information processing showed improvement in the propentofylline group.
- A trend towards slowing cognitive deterioration was observed in patients treated with propentofylline.
Conclusions:
- Propentofylline demonstrates a positive effect on cerebral glucose metabolism and cognitive function in VD patients.
- Metabolic and neuropsychological changes are closely linked in VD.
- These findings support the need for large-scale clinical trials to confirm the therapeutic efficacy of propentofylline for vascular dementia.